Picard Medical Inc Dossier
Qualitative Analysis
Business overview
Picard Medical, Inc. (NYSE American: PMI) operates as a medical technology holding company focused on mechanical circulatory support. Its primary asset is its wholly owned subsidiary, SynCardia Systems, LLC, which develops, manufactures, and commercializes the SynCardia Total Artificial Heart (STAH). The STAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from end-stage biventricular heart failure. It remains the first and only commercially available total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada. Over 2,100 STAH implants have been performed globally across 27 countries. Picard is actively developing its next-generation platform, the Emperor Total Artificial Heart, which features an electromechanically actuated, driverless system designed to eliminate external hardware and improve patient mobility.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Development of a next-generation, fully implantable, driverless total artificial heart system (codenamed 'Emperor') powered by small electromechanical drivers to eliminate the need for external pneumatic drivers while preserving the physiological autoregulation of the SynCardia platform.
Expected impact: Aims to redefine long-term mechanical heart replacement, improve patient mobility, reduce infection risks, and expand the eligible patient base.
Operational focus on reducing per-unit manufacturing costs, scaling production capacity toward 3,000 units per year, and introducing a lower-cost pneumatic driver.
Expected impact: Aims to build a clear path toward long-term profitability and sustainability, building on the positive 24% gross margin achieved in Q1 2026.
Active efforts to strengthen the balance sheet, reduce outstanding liabilities, and simplify the capital structure through debt repayment, equity settlements, and warrant exchanges.
Expected impact: Aims to eliminate complex derivative liabilities, reduce financing-related complexity, and maintain the company's public listing status.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of the assets and technology of SynCardia Systems, the developer and manufacturer of the world's first and only FDA and Health Canada approved temporary Total Artificial Heart (STAH), to serve as the core operating platform for Picard Medical.
Financial impact: Formed the primary revenue-generating business of Picard Medical, contributing $4.9 million in total revenue for the fiscal year 2025.
Strategic Partnerships
Collaboration on the development of the next-generation Emperor Total Artificial Heart program, leveraging Hydrix's engineering expertise to design the electromechanically actuated, driverless system.
Terms: Specific financial terms of the collaboration agreement were not disclosed.
Collaboration with leading researchers and surgical teams to conduct preclinical acute in vivo implant studies for the Emperor Total Artificial Heart platform.
Terms: Research collaboration support; specific financial terms were not disclosed.